JP2016512693A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512693A5 JP2016512693A5 JP2016503010A JP2016503010A JP2016512693A5 JP 2016512693 A5 JP2016512693 A5 JP 2016512693A5 JP 2016503010 A JP2016503010 A JP 2016503010A JP 2016503010 A JP2016503010 A JP 2016503010A JP 2016512693 A5 JP2016512693 A5 JP 2016512693A5
- Authority
- JP
- Japan
- Prior art keywords
- reagent
- providing
- cell
- tissue sample
- chaotrope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003153 chemical reaction reagent Substances 0.000 claims 11
- 239000002738 chelating agent Substances 0.000 claims 7
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 6
- 238000004321 preservation Methods 0.000 claims 5
- QZKOOEFIMWKZPK-UHFFFAOYSA-N 2-[(6-carbamimidoyl-1h-benzimidazol-2-yl)methyl]-3h-benzimidazole-5-carboximidamide Chemical compound C1=C(C(N)=N)C=C2NC(CC3=NC4=CC=C(C=C4N3)C(=N)N)=NC2=C1 QZKOOEFIMWKZPK-UHFFFAOYSA-N 0.000 claims 4
- 102000016267 Leptin Human genes 0.000 claims 4
- 108010092277 Leptin Proteins 0.000 claims 4
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 claims 4
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 4
- 229940039781 leptin Drugs 0.000 claims 4
- 230000002503 metabolic effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000003607 modifier Substances 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 claims 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 2
- 230000001640 apoptogenic effect Effects 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 claims 2
- 235000005956 Cosmos caudatus Nutrition 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000010195 expression analysis Methods 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003880 polar aprotic solvent Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical group [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 claims 1
- 125000000647 trehalose group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361798627P | 2013-03-15 | 2013-03-15 | |
| US61/798,627 | 2013-03-15 | ||
| PCT/US2014/029198 WO2014144682A1 (en) | 2013-03-15 | 2014-03-14 | Methods and reagents for maintaining the viability of cancer cells in surgically removed tissue |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512693A JP2016512693A (ja) | 2016-05-09 |
| JP2016512693A5 true JP2016512693A5 (cg-RX-API-DMAC7.html) | 2017-04-13 |
| JP6465857B2 JP6465857B2 (ja) | 2019-02-06 |
Family
ID=51528685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503010A Active JP6465857B2 (ja) | 2013-03-15 | 2014-03-14 | 外科的に摘出された組織における癌細胞の生存能を維持するための方法および試薬 |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US9113623B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2970878B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6465857B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN105121629B (cg-RX-API-DMAC7.html) |
| CA (1) | CA2941929C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1120801T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2970878T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2684582T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20181352T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE039933T2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT2970878T (cg-RX-API-DMAC7.html) |
| PL (1) | PL2970878T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2970878T (cg-RX-API-DMAC7.html) |
| RS (1) | RS57900B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI2970878T1 (cg-RX-API-DMAC7.html) |
| SM (1) | SMT201800457T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014144682A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2970878T (lt) | 2013-03-15 | 2018-11-12 | Truckee Applied Genomics, Llc | Vėžio ląstelių chirurginiu būdu pašalintame audinyje gyvybingumo palaikymo būdai ir reagenatai |
| EP3224359B1 (en) | 2014-11-25 | 2023-10-25 | Bio-Rad Laboratories, Inc. | Arginine improves polymerase storage stability |
| CN107333750A (zh) * | 2017-06-11 | 2017-11-10 | 成都吱吖科技有限公司 | 一种长时血液细胞稳定剂 |
| WO2021055170A1 (en) * | 2019-09-17 | 2021-03-25 | Longhorn Vaccines And Diagnostics, Llc | Multipurpose compositions for collecting and transporting biological material |
| WO2022010916A1 (en) * | 2020-07-07 | 2022-01-13 | Truckee Applied Genomics, Llc | Cell preservation reagents and methods of use |
| CN117063915A (zh) * | 2023-08-17 | 2023-11-17 | 镜像绮点(上海)细胞技术有限公司 | 原代肿瘤细胞冻存液 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5409826A (en) * | 1993-06-08 | 1995-04-25 | Coulter Corporation | Preserved, non-infectious control cells prepared by the modulation or modification of normal cells |
| JP2000509018A (ja) * | 1996-03-26 | 2000-07-18 | イーライ・リリー・アンド・カンパニー | 肥満タンパク質製剤 |
| US20010007673A1 (en) | 1999-11-12 | 2001-07-12 | Merrill Seymour Goldenberg | Sustained-release delayed gels |
| US20080064108A1 (en) | 1997-12-10 | 2008-03-13 | Tony Baker | Urine Preservation System |
| US7569342B2 (en) | 1997-12-10 | 2009-08-04 | Sierra Molecular Corp. | Removal of molecular assay interferences |
| JP2001526051A (ja) | 1997-12-10 | 2001-12-18 | シエラ ダイアグノスティクス,インク. | 体液中のdnaを保存するための方法及び試薬 |
| DE60116673T2 (de) * | 2000-12-04 | 2006-08-10 | Lymphotec Inc. | Zellkonservierungsflüssigkeit und verfahren zur zellkonservierung mit dieser flüssigkeit |
| KR20020066778A (ko) | 2001-02-13 | 2002-08-21 | 한국과학기술연구원 | 체내 난흡수 물질의 흡수촉진용 조성물과 제형 및 그의제조방법 |
| WO2008111981A1 (en) | 2007-03-14 | 2008-09-18 | Sierra Molecular Corporation | Compositions, systems, and methods for preservation of macromolecules |
| US20040214203A1 (en) * | 2002-12-12 | 2004-10-28 | Oncotech, Inc. | Genes related to sensitivity and resistance to chemotherapeutic drug treatment |
| US8793895B2 (en) * | 2006-02-10 | 2014-08-05 | Praxair Technology, Inc. | Lyophilization system and method |
| KR20090098957A (ko) | 2006-09-12 | 2009-09-18 | 시에라 몰레큘러 코포레이션 | 카오트로프의 완충용액을 사용하는 핵산을 대상으로 하는 분자분석 간섭의 제거 |
| US8080645B2 (en) * | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
| US8652782B2 (en) * | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
| AU2007308865A1 (en) | 2006-10-27 | 2008-05-02 | Sierra Molecular Corporation | Penetratable septum cap |
| EP2094846B8 (en) | 2006-12-13 | 2013-10-16 | Roche Diagnostics GmbH | Use of tde for the isolation of nucleic acids |
| JP2010535013A (ja) | 2007-03-14 | 2010-11-18 | シエラ モレキュラー コーポレイション | 細胞および/または高分子の保存および/または安定化のための組成物、システムおよび方法 |
| CA2705417A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| US20100003748A1 (en) * | 2008-07-03 | 2010-01-07 | Tony Baker | Compositions, systems, and methods for stabilization of a cell and/or macromolecule |
| US20110165611A1 (en) | 2008-09-04 | 2011-07-07 | Chun Li | Dual modality detection of apoptosis |
| US9133343B2 (en) | 2009-11-30 | 2015-09-15 | Enzo Biochem, Inc. | Dyes and compositions, and processes for using same in analysis of protein aggregation and other applications |
| CN102318597B (zh) * | 2011-08-19 | 2013-04-03 | 张雪云 | 一种液基细胞保存液组合物及其制备方法 |
| LT2970878T (lt) | 2013-03-15 | 2018-11-12 | Truckee Applied Genomics, Llc | Vėžio ląstelių chirurginiu būdu pašalintame audinyje gyvybingumo palaikymo būdai ir reagenatai |
-
2014
- 2014-03-14 LT LTEP14763797.9T patent/LT2970878T/lt unknown
- 2014-03-14 PT PT14763797T patent/PT2970878T/pt unknown
- 2014-03-14 JP JP2016503010A patent/JP6465857B2/ja active Active
- 2014-03-14 CN CN201480014875.5A patent/CN105121629B/zh active Active
- 2014-03-14 DK DK14763797.9T patent/DK2970878T3/en active
- 2014-03-14 CN CN202011428224.4A patent/CN112806352A/zh active Pending
- 2014-03-14 HU HUE14763797A patent/HUE039933T2/hu unknown
- 2014-03-14 ES ES14763797.9T patent/ES2684582T3/es active Active
- 2014-03-14 HR HRP20181352TT patent/HRP20181352T1/hr unknown
- 2014-03-14 EP EP14763797.9A patent/EP2970878B1/en active Active
- 2014-03-14 EP EP18173516.8A patent/EP3581643A1/en not_active Withdrawn
- 2014-03-14 RS RS20180976A patent/RS57900B1/sr unknown
- 2014-03-14 US US14/211,578 patent/US9113623B2/en active Active
- 2014-03-14 CA CA2941929A patent/CA2941929C/en active Active
- 2014-03-14 SI SI201430839T patent/SI2970878T1/sl unknown
- 2014-03-14 WO PCT/US2014/029198 patent/WO2014144682A1/en not_active Ceased
- 2014-03-14 SM SM20180457T patent/SMT201800457T1/it unknown
- 2014-03-14 PL PL14763797T patent/PL2970878T3/pl unknown
-
2015
- 2015-05-01 US US14/702,643 patent/US9565852B2/en active Active
- 2015-05-14 US US14/712,750 patent/US9445586B2/en active Active
-
2016
- 2016-02-02 US US15/013,541 patent/US9949474B2/en active Active
-
2017
- 2017-02-13 US US15/431,478 patent/US10772318B2/en active Active
-
2018
- 2018-08-23 CY CY181100877T patent/CY1120801T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512693A5 (cg-RX-API-DMAC7.html) | ||
| HUS2500003I1 (hu) | Módosított IX-es faktor, valamint készítmények, eljárások és alkalmazások sejtekbe, szervekbe és szövetekbe történõ géntranszferhez | |
| BR112015017405A2 (pt) | composições que incluem agentes hidrofobizantes e estabilizantes e métodos para preparação e utilização das mesmas | |
| EP3310931A4 (en) | CRISPR / CAS9 COMPLEX FOR INTRODUCING A FUNCTIONAL POLYPEPTIDE IN CELLS OF A BLOOD CELL LINE | |
| EP4265250A3 (en) | Solid forms of an ask1 inhibitor | |
| MX2016010266A (es) | Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso. | |
| EA201691826A1 (ru) | Способ использования графена и других двухмерных материалов in vivo и in vitro | |
| EP3564356A4 (en) | SOLUTION FOR CRYOPRESERVATION, CRYOGENIZATION PRODUCT, AND METHOD FOR CRYOPRESERVATION OF ANIMAL CELLS OR ANIMAL TISSUES | |
| JP2015061520A5 (cg-RX-API-DMAC7.html) | ||
| NZ739339A (en) | Apoptosis signal-regulating kinase inhibitor | |
| SI2958913T1 (sl) | Sfingozin-1-fosfat receptor agonisti, postopki za njegovo pripravo in farmacevtski sestavki, ki ga vsebujejo kot aktivno sredstvo | |
| AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
| UA117103C2 (uk) | Сполука, яка має активність агоніста глюкагону | |
| WO2015153772A3 (en) | Zirconium-89 oxine complex as a cell labeling agent for positron emission tomography | |
| EP3202409A4 (en) | Composition, cell construct, islet transplant kit, islet cell transplant therapeutic agent and blood sugar reducing agent, composition including islets, kit including islets, and islet transplant therapeutic agent and blood sugar reducing agent | |
| DK3079675T3 (da) | Farmaceutisk sammensætning indeholdende nikotinsyre og/eller nikotinamid til anvendelse til gavnlig påvirkning af blodlipidniveauer ved modificering af tarmmikrobiataen | |
| BR112017020745A2 (pt) | métodos de estratamento de pacientes para tratamento com agonistas de receptor-a de ácido retinoico. | |
| DK3232780T3 (da) | Vandige adjuvans-sammensætninger, der indeholder elektrolyt, sammensætninger, som indeholder et aktivt stof, og anvendelse deraf | |
| BR112013021784A2 (pt) | composição de reagente, e, método para a recuperação de um metal de uma solução aquosa | |
| MX389168B (es) | Procedimiento para preparar inhibidores de la glucosilceramida sintasa. | |
| CL2015002065A1 (es) | Método para mejorar composiciones de sal de nitrato por medio de ácido nítrico para su uso con medio de transferencia de calor o medio de almacenamiento de calor. | |
| NZ727749A (en) | Use of anti-aging glycopeptides to enhance beta cell health, survival and improve transplant outcome | |
| FR3033335B1 (fr) | Procede non radioactif de determination de l'action cytolytique d'un agent vis-a-vis de cellules cibles, son utilisation et kit associe | |
| WO2015171826A8 (en) | Steap3 as a biochemical marker of red blood cell storage and toxicity | |
| JP2014137599A5 (cg-RX-API-DMAC7.html) |